FCF Life Science Research

FCF engages in research on recent financing trends in the Life Science sector, i.e. biotechnology, pharma and med-tech. FCF primarily focuses on the latest activities in the equity capital markets: Venture Capital, Initial Public Offerings (IPO) and Equity Valuations. The findings are regularly published in

FCF LIFE SCIENCE VENTURE CAPITAL MONITOR

Life Science Venture Capital Monitor is a monthly published overview of biotechnology, pharmaceutical, medical technology and healthcare technology companies, displaying venture capital financing trends in the European life science industry.

FCF LIFE SCIENCE VENTURE CAPITAL REPORT

The FCF Life Science Venture Capital Report analyses the latest VC funding activities in the Life Science sector. The report provides a detailed investigation on funding dynamics in Europe and the US

  • Sub-sector Analysis
  • Deal Volume Analysis
  • Investor Analysis
  • Cross-Border Analysis
  • Fund Raising Analysis

FCF LIFE SCIENCE PUBLIC EQUITY MONITOR

The FCF Life Science Public Equity Monitor comprises of listed small- and midcap companies, headquartered in Europe, from the biotechnology, pharma and med-tech sectors. The report is a derivative of the FCF Valuation Monitor, adjusted to valuation and performance metrics suited for the Life Science sector.

The analysis focuses on

  • Performance and Valuation Analysis
  • Break-even Analysis
  • Share Price Potential Analysis
  • Shareholder Analysis
  • Liquidity Analysis

FCF LIFE SCIENCE IPO REPORT

The FCF Life Science IPO Report examines recent IPO trends in the Life Science sector, with a strong focus on the comparison of European and US characteristics

  • Size Segment Analysis
  • Sub-sector Analysis
  • Investor Analysis
  • Liquidity Analysis
  • Share Pricing / Trading Analysis
  • Underwriter Analysis

LIFE SCIENCE PUBLICATIONS

RECENT LIFE SCIENCE TRANSACTIONS

Vasopharm GmbH

Transaction Support
July 2019

AMW GmbH

EIB Debt Facility
November 2017
€ 25 million
numares transaction

numares AG

Capital Increase
November 2017
€ 11 million

MagForce AG

EIB Debt Facility
August 2017
€ 35 million